Medicamen Biotech allots preferential issue
Medicamen Biotech (BSE: MEDICAMEQ) said it has allotted preferential issue. The company is valued at about ₹347 crore.
What happened
Medicamen Biotech (BSE: MEDICAMEQ) informed the stock exchanges on 23 October 2026 at 12:01 PM that it has allotted preferential issue.
Company snapshot
Medicamen Biotech is a micro-cap company, with a market value of about ₹347 crore.
The stock last traded at ₹255.7, against a 52-week range of ₹212.4–₹447.7 (42.9% below the high).
Before this filing the shares had moved −19.4% over the month and +7.9% over three months. Average daily turnover over the last 20 sessions was about ₹0.63 crore.
Promoters held 40.46% at the end of Q1 FY27. Foreign institutions owned 0.07% and domestic institutions 0.40%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 43 | 2.2 | 1.18 |
| Q2 FY26 | 47 | 2.7 | 1.56 |
| Q3 FY26 | 47 | 2.2 | 1.21 |
| Q4 FY26 | 61 | 3.9 | 3.28 |
| Q1 FY27 | 48 | 2.1 | 1.36 |
What history shows
BCEIE has no earlier fund raising filing from this company on record since May 2026.
Market-wide, 1,624 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 48% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- How the money raised is used and, for equity instruments, the dilution for existing shareholders.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.